Jae-Seung Paick

Seoul National University Hospital, Sŏul, Seoul, South Korea

Are you Jae-Seung Paick?

Claim your profile

Publications (152)376.11 Total impact

  • Young Ju Lee · Sung Yong Cho · Jae-Seung Paick · Soo Woong Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the impact of 2010 World Health Organization (WHO) reference values in patients who underwent microsurgical varicocelectomy. This retrospective cohort study included 206 men who underwent microsurgical varicocelectomy for a clinical varicocele with at least 1 abnormal semen parameter according to the 1999 WHO criteria. The preoperative semen analysis findings were reclassified according to the 2010 WHO criteria, and an improved seminal result after varicocelectomy was defined as a ≥20% increase in sperm count or motility. Semen results of 114 men (55.3%) were reclassified as being above the reference values according to the 2010 WHO criteria. Among those with below reference values, 79.3% and 34.8% showed improved sperm counts and motility, respectively. However, in patients whose semen results converted to normal, 47.4% and 20.2% showed improved sperm counts and motility, respectively. Among those whose semen results were normal on the 2010 criteria, 58.8% showed improved sperm count or motility after microsurgical varicocelectomy. More than half of the patients whose semen results converted to normal on the 2010 WHO criteria showed improved seminal results after microsurgical varicocelectomy. It is necessary to reconsider the 2010 WHO criteria when determining the surgical indication for microsurgical varicocelectomy. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urology 04/2015; 85(4). DOI:10.1016/j.urology.2015.01.012 · 2.19 Impact Factor
  • Source

    The Journal of Urology 04/2015; 193(4):e136. DOI:10.1016/j.juro.2015.02.341 · 4.47 Impact Factor
  • Source

    The Journal of Urology 04/2015; 193(4):e139. DOI:10.1016/j.juro.2015.02.347 · 4.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The method of administration of oral phosphodiesterase-5 inhibitors has been expanded to once-daily repeated administration with lower initial dosage than on-demand administration. The aim of this study was to evaluate the efficacy and safety of once-daily udenafil as a treatment for erectile dysfunction (ED) for intermediate-term period. This multicenter, randomized, double-blind clinical trial included 346 ED patients (placebo, udenafil 50 mg, udenafil 75 mg). Subjects were treated with each medication once daily for 24 weeks. Subjects were asked to complete the International Index of Erectile Function (IIEF)-erectile function (EF) domain at baseline, 12 weeks, and 24 weeks and the development of adverse drug reactions (ADRs) was inspected. Both dosages of udenafil induced a significant increase in IIEF-EF compared with placebo at both 12 and 24 weeks. When patients were divided according to the severity of baseline EF score, significant improvement was observed only with udenafil 75 mg regardless of the degree of ED. At 24 weeks, the proportions of patients who reported a return to normal EF (IIEF-EF over 26) were 39.1% for udenafil 50 mg and 47.0% for udenafil 75 mg. In terms of safety, ADRs were observed in 6.1%, 12.9%, and 17.9% for placebo, udenafil 50 mg, and 75 mg, respectively. Although a statistically higher rate of ADRs was observed in the udenafil 75 mg group (P = 0.024), the majority were mild and recovered without treatment. Once-daily administration of udenafil 50 mg and 75 mg for 24 weeks resulted in improvement of EF. In particular, udenafil 75 mg improves EF regardless of the baseline degree of ED. Moon KH, Ko YH, Kim SW, Moon DG, Kim JJ, Park NC, Lee SW, Paick J-S, Ahn TY, Chung WS, Min KS, Park JK, Yang DY, and Park K. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: Results from a randomized multicenter placebo-controlled clinical trial. J Sex Med 2015;12:1194–1201.
    Journal of Sexual Medicine 03/2015; 12(5). DOI:10.1111/jsm.12862 · 3.15 Impact Factor
  • Source
    Myong Kim · Luis Ramirez · Changwon Yoo · Minsoo Choo · Jae-Seung Paick · Seung-June Oh ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To identify the factors affecting the surgical decisions of experienced physicians when treating patients with lower urinary tract symptoms that are suggestive of benign prostatic hyperplasia (LUTS/BPH). Patients with LUTS/BPH treated by two physicians between October 2004 and August 2013 were included in this study. The causal Bayesian network (CBN) model was used to analyze factors influencing the surgical decisions of physicians and the actual performance of surgery. The accuracies of the established CBN models were verified using linear regression (LR) analysis. A total of 1,108 patients with LUTS/BPH were analyzed. The mean age and total prostate volume (TPV) were 66.2 (±7.3, standard deviation) years and 47.3 (±25.4) mL, respectively. Of the total 1,108 patients, 603 (54.4%) were treated by physician A and 505 (45.6%) were treated by physician B. Although surgery was recommended to 699 patients (63.1%), 589 (53.2%) actually underwent surgery. Our CBN model showed that the TPV (R=0.432), treating physician (R=0.370), bladder outlet obstruction (BOO) on urodynamic study (UDS) (R=0.324), and International Prostate Symptom Score (IPSS) question 3 (intermittency; R=0.141) were the factors directly influencing the surgical decision. The transition zone volume (R=0.396), treating physician (R=0.340), and BOO (R=0.300) directly affected the performance of surgery. Compared to the LR model, the area under the receiver operating characteristic curve of the CBN surgical decision model was slightly compromised (0.803 vs. 0.847, P<0.001), whereas that of the actual performance of surgery model was similar (0.801 vs. 0.820, P=0.063) to the LR model. The TPV, treating physician, BOO on UDS, and the IPSS item of intermittency were factors that directly influenced decision-making in physicians treating patients with LUTS/BPH.
    International neurourology journal 12/2014; 18(4):198-205. DOI:10.5213/inj.2014.18.4.198 · 1.06 Impact Factor
  • Source
    Myong Kim · Abhilash Cheeti · Changwon Yoo · Minsoo Choo · Jae-Seung Paick · Seung-June Oh ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To identify non-invasive clinical parameters to predict urodynamic bladder outlet obstruction (BOO) in patients with benign prostatic hyperplasia (BPH) using causal Bayesian networks (CBN). Subjects and Methods From October 2004 to August 2013, 1,381 eligible BPH patients with complete data were selected for analysis. The following clinical variables were considered: age, total prostate volume (TPV), transition zone volume (TZV), prostate specific antigen (PSA), maximum flow rate (Qmax), and post-void residual volume (PVR) on uroflowmetry, and International Prostate Symptom Score (IPSS). Among these variables, the independent predictors of BOO were selected using the CBN model. The predictive performance of the CBN model using the selected variables was verified through a logistic regression (LR) model with the same dataset. Results Mean age, TPV, and IPSS were 6.2 (±7.3, SD) years, 48.5 (±25.9) ml, and 17.9 (±7.9), respectively. The mean BOO index was 35.1 (±25.2) and 477 patients (34.5%) had urodynamic BOO (BOO index ≥40). By using the CBN model, we identified TPV, Qmax, and PVR as independent predictors of BOO. With these three variables, the BOO prediction accuracy was 73.5%. The LR model showed a similar accuracy (77.0%). However, the area under the receiver operating characteristic curve of the CBN model was statistically smaller than that of the LR model (0.772 vs. 0.798, p = 0.020). Conclusions Our study demonstrated that TPV, Qmax, and PVR are independent predictors of urodynamic BOO.
    PLoS ONE 11/2014; 9(11):e113131. DOI:10.1371/journal.pone.0113131 · 3.23 Impact Factor
  • Min Chul Cho · Seung Beom Ha · Seung-June Oh · Soo Woong Kim · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To compare serial changes of postoperative storage symptoms between PVP and HoLEP, and to identify the predictors influencing postoperative improvement of storage symptoms. Methods: A total of 486 men (PVP group: 213 cases; HoLEP group: 273 cases), in whom 12-month follow-up data were available, were included in this retrospective study. Surgical outcomes were evaluated at 1-, 3-, 6-, and 12 months postoperatively using the IPSS, uroflowmetry with post-void residual urine volume (PVR) and serum PSA levels. Improvement of storage symptoms was defined as a reduction by ≥50 % of the subtotal storage symptom score postoperatively compared to baseline. Results: In both PVP and HoLEP groups, total IPSS, quality-of-life index, frequency score, nocturia score, maximum flow rate and PVR were significantly decreased compared to baseline starting from 1 month after surgery. Whereas urgency score was numerically increased compared to baseline at 1 month after PVP, it was reduced compared to baseline at 1 month after HoLEP. While the subtotal storage symptom score was significantly decreased compared to baseline starting from 3 months after PVP, it was significantly reduced starting from 1 month after HoLEP. On logistic regression analysis, a higher baseline subtotal storage symptom score was the only independent predictor of improvement in storage symptoms after PVP or HoLEP. Conclusions: Our data suggest that improvement in storage symptoms after HoLEP begins earlier than that after PVP. Also, this study indicates that patients with more severe baseline storage symptoms have a higher likelihood of improvement after PVP or HoLEP compared to those with less severe symptoms.
    World Journal of Urology 11/2014; 33(8). DOI:10.1007/s00345-014-1424-0 · 2.67 Impact Factor
  • Min Chul Cho · Kwanjin Park · Soo Woong Kim · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether Rho-kinase inhibition could improve corporal veno-occlusive dysfunction (CVOD) by suppression of apoptosis and fibrosis via normalization of Rho-kinase-driven pathways related to the two structural alterations in rat models of CN crush injury (CNI). Thirty 10-week-old male Sprague-Dawley rats were divided equally into three groups: sham surgery (S), CNI (I), and CNI treated with fasudil (F). The F group was treated with daily administration of fasudil (30mg/kg) for 4-weeks from the following day after surgery. Electrostimulation and dynamic infusion cavernosometry (DIC) were performed at 4-weeks postoperatively. Penile tissue was processed for immunohistochemistry, double immunofluorescence, Masson's trichrome staining, TUNEL, caspase-3 activity assay, and Western blotting. The I group showed significantly lower intracavernous pressure (ICP)/mean arterial pressure, higher maintenance and drop rates than S group. Rho-kinase inhibition in F group restored erectile responses and DIC parameters. Increased apoptosis, decreased immunohistochemical staining of α-SMA, and increased caspase-3 activity were noted in I group. Densitometry showed that I group had increased ROCK1 expression, increased MYPT1 phosphorylation, decreased Akt phosphorylation, decreased Bad phosphorylation, and decreased Bcl2/Bax ratio. Significantly decreased smooth muscle/collagen ratio and increased content of phospho-cofilin in fibroblasts were observed in I group. Increased cofilin phosphorylation, a downstream effector of LIMK2, was noted in I group. Rho-kinase inhibition in F group alleviated the histological and molecular dysregulation. Our data suggest that early inhibition of Rho-kinase after CNI may prevent both corporal apoptosis and fibrosis by suppressing Akt/Bad/Bax/caspase-3 and LIMK2/cofilin pathways, preventing CVOD and erectile dysfunction. Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
    The Journal of Urology 10/2014; 193(5). DOI:10.1016/j.juro.2014.10.099 · 4.47 Impact Factor
  • Source
    Young Ju Lee · Seung Jun Son · Jae-Seung Paick · Soo Woong Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose To evaluate the clinical usefulness of preoperative CT voiding cystourethrography (CT-VCUG) using 16-multidetector computed tomography for female urethral diverticula. Materials and Methods Preoperative CT-VCUG was performed in 15 consecutive patients who underwent urethral diverticulectomy from May 2004 to December 2012. The result of preoperative cystourethroscopy and surgical findings were recorded by a single surgeon and CT-VCUG findings including the location of osita were retrospectively reviewed by another urologist who was blinded to the surgical finding. The location of the ostium detected on CT-VCUG was compared descriptively with the intraoperative surgical and preoperative cystourethroscopic findings. Results A total of 14 consecutive patients who underwent preoperative CT-VCUG and urethral diverticulectomy were included in the analysis. Ostia were detected on CT-VCUG in all cases, whereas ostia were identified in 10 patients (71.4%) by cystourethroscopy. Ostia were located between the 4 and 8 o’clock direction. Mean distance from the bladder neck to the ostium was 24.2 mm. Circumferential and horseshoe shaped diverticula were observed in 6 and 4 patients, respectively. The surgical findings correlated well with the CT findings. Conclusions Preoperative CT-VCUG can be useful in identifying the ostia of urethral diverticula in patients scheduled for urethral diverticulectomy and can provide structural information, useful to establish surgical strategy.
    PLoS ONE 09/2014; 9(9):e107448. DOI:10.1371/journal.pone.0107448 · 3.23 Impact Factor
  • Woo Suk Choi · Ja Hyeon Ku · Seung-June Oh · Soo Woong Kim · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To evaluate changes of nocturnal polyuria (NP) after holmium laser enucleation of the prostate (HoLEP) in patients with nocturia preoperatively. Patients and Methods This retrospective study included patients who underwent HoLEP for benign prostatic hyperplasia and recorded 3-day frequency-volume chart strictly. Patients who had a history of prostate cancer, sleep apnea, renal failure, heart failure, or medication of desmopressin were excluded. Nocturia is defined as ≥1 void at night, and NP is defined by nocturnal polyuria index (NPI) >33%. Among 472 patients included in the final analysis, 352 men (74.6%) presented nocturia preoperatively. Among those, 205 men (58.2%) who had NP preoperatively were allocated to group NP, and 147 men who did not were allocated to group non-NP. Results In total patients, nocturnal frequency was decreased significantly starting from 3 months after the HoLEP. In NP group, mean value of NPI decreased by 4.1% ± 10.7%, 6.0% ± 9.4%, 6.2% ± 9.5%, and 4.8% ± 11.4% at postoperative months 1, 3, 6, and 12, respectively. The proportion of patients who showed decreased NPI to the normal range (≤33%) were 32.5%, 36.1%, 37.7%, and 31.0% at postoperative months 1, 3, 6, and 12, respectively. On receiver operating characteristics curve analysis, an absolute reduction of NPI of ≥6.0% was shown as a significant predictor for improved nocturia (≥50% reduction of nocturnal frequency). Conclusion In our study, the improvement of NP after HoLEP was observed. This suggests that relieving lower urinary tract obstruction has a positive influence on NP, and it could be a new strategy for treatment of NP.
    Urology 09/2014; 84(3):650–656. DOI:10.1016/j.urology.2014.05.040 · 2.19 Impact Factor
  • Source
    Kyoung Rok Kim · Jun-Gyo Suh · Jae-Seung Paick · Soo Woong Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Penile circular fasciocutaneous flap urethroplasty is a useful technique for a long anterior urethral stricture due to the flap's hairless nature and ample length. We investigated the surgical outcomes of urethroplasty for a complex anterior urethral stricture, performed using a penile circular fasciocutaneous flap. Materials and Methods Between 2008 and 2013, we performed a retrospective review of 29 patients who underwent urethroplasty using a penile circular fasciocutaneous flap and had at least 6 months of follow-up. A total of 20 cases utilized only a fasciocutaneous flap, while 9 cases combined a fasciocutaneous flap with other surgery. Success was defined as no requirement of additional urethral instrumentation. Results The overall success rate was 68.9% (20 out of 29 cases) at a median follow-up of 19 months. Furthermore, fasciocutaneous flap urethroplasty rendered the actual stricture-free rate of 79.3%. The location of recurrence was mostly at the junction of the flap. Among 9 surgical failures, 5 cases were treated successfully by using an additional surgical procedure. Fistula repair was needed in 1 case 4 months later. Further, periodic urethral dilation was performed in the remaining 3 cases. The failure rate was significantly higher in patients with suprapubic cystostomy than in patients without suprapubic cystostomy. The most common complication was post-micturition dribbling. Conclusions Penile circular fasciocutaneous flap urethroplasty is a useful method for the reconstruction of a long anterior urethral stricture. A sufficient healthy margin should be acquired for better surgical results due to the fact that most recurrence occurs at the junction of the flap.
    08/2014; 32(2):87-92. DOI:10.5534/wjmh.2014.32.2.87
  • Source
    Myong Kim · Sang Hoon Song · Ja Hyeon Ku · Seung-June Oh · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To identify predictors of incidental prostate cancer following Holmium laser enucleation of the prostate (HoLEP). Methods: We retrospectively analyzed 458 consecutive patients who underwent HoLEP. Patients were classified into two groups: patients who received prostate biopsy prior to HoLEP (biopsy group, n = 174) and patients who did not (non-biopsy group, n = 284). The two groups were compared. Logistic regression analysis was performed to determine the predictive factors. Results: A total of 27 patients (5.9 %) were incidentally diagnosed with prostate cancer. The incidence of prostate cancer was not significantly different between the two groups (biopsy group vs. non-biopsy group: 6.9 vs. 5.3 %, p = 0.48). Using multivariate analysis, a hypoechoic lesion identified by transrectal ultrasonography (TRUS) was the only predictor of incidental prostate cancer (odds ratio 2.829; 95 % confidence interval 1.061-7.539; p = 0.038). In the biopsy group, there were no significant differences in baseline characteristics including prostate size, prostate-specific antigen (PSA), PSA density, digital rectal examination (DRE) findings, and TRUS findings, between patients with and without prostate cancer. However, in the non-biopsy group, a hypoechoic lesion was found more frequently in patients with prostate cancer (prostate cancer vs. benign prostatic hyperplasia: 20.0 vs. 3.3 %, p = 0.02). Conclusions: Prior negative prostate biopsy does not rule out the possibility of prostate cancer after HoLEP. The presence of a hypoechoic lesion on TRUS might be helpful to predict incidental prostate cancer after HoLEP in patients with normal PSA and negative DRE. Prostate biopsy prior to HoLEP should be considered in these patients.
    International Urology and Nephrology 07/2014; 46(11). DOI:10.1007/s11255-014-0777-z · 1.52 Impact Factor
  • Source
    Sung Han Kim · Hyung-Kook Yang · Hahn-Ey Lee · Jae-Seung Paick · Seung-June Oh ·
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to prospectively evaluate the influence of holmium laser enucleation of the prostate (HoLEP) on the overall postoperative sexual function of benign prostatic hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS) and to explore the relationship between sexual function and LUTS. From January 2010 to December 2011, sixty sexually active consecutive patients with BPH who underwent HoLEP were prospectively enrolled in the study. All patients filled out the Male Sexual Health Questionnaire (MSHQ) for evaluation of their overall sexual function and the International Prostatic Symptom Score (IPSS) for pre- and post-operative 6 months evaluation of their voiding symptoms. The LUTS and sexual function changes were statistically analyzed. The preoperative and 6 months postoperative status of the patients was compared using uroflowmetry and IPSS questionnaires. The analysis revealed significant improvements following HoLEP. Among the sub-domains of the MSHQ, postoperative sexual function, including erection, ejaculation, sexual satisfaction, anxiety or sexual desire, did not significantly change after HoLEP (P > 0.05), whereas satisfaction scores decreased slightly due to retrograde ejaculation in 38 patients (63.3%). Sexual satisfaction improved significantly and was correlated with the improvements of all LUTS and the quality-of-life (QoL) domains in IPSS after surgery (QoL; relative risk [RR]: -0.293; total symptoms, RR: -0.411; P < 0.05). The nocturia score was associated with the erectile function score (odds ratio 0.318, P = 0.029). The change in ejaculatory scores did not show significant association with IPSS scores. HoLEP did not influence overall sexual function, including erectile function. In addition, sexual satisfaction improved in proportion with the improvement of LUTS.
    Asian Journal of Andrology 06/2014; 16(6). DOI:10.4103/1008-682X.132469 · 2.60 Impact Factor
  • Source
    Min Chul Cho · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Erectile dysfunction (ED) is often perceived by both patients and sexual partners as a serious problem that can jeopardize quality of life, psychosocial or emotional well-being, and the partnership in the long term. Since their introduction, oral phosphodiesterase type 5 inhibitors (PDE5Is) have been found to be highly effective and well tolerated, and are available as the first-line therapy for the treatment of ED. Udenafil is one of the selective PDE5Is made available in recent years for the treatment of ED. Udenafil has clinical properties of both relatively rapid onset and long duration of action due to its pharmacokinetic profile, thereby providing an additional treatment option for ED men to better suit individual needs. There is positive evidence that udenafil is effective and well tolerated in the treatment of ED of a broad spectrum of etiologies or severity. Udenafil is as effective in the treatment of diabetes mellitus-associated ED as other PDE5Is. Due to the clinical property of relatively long duration of action, udenafil may be another option in daily dosing treatment for ED, as suggested by its favorable efficacy and safety profile. Most adverse effects reported from clinical trials are mild or moderate in severity, without any serious adverse event, with headache and flushing being the most common. Also, the concomitant use of anti-hypertensive drugs or alpha-1-blockers does not significantly affect the efficacy and safety profile of udenafil. However, additional studies with larger cohorts including prospective, multicenter, comparative studies with patients of different ethnicities are needed to further validate the favorable findings of udenafil in the treatment of ED.
    Therapeutics and Clinical Risk Management 05/2014; 10(1):341-354. DOI:10.2147/TCRM.S39727 · 1.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: A large post-void residual (PVR) has been considered to be an indicator for the need to further management. However, the threshold level of PVR has been not defined. We determined the PVR volume by using bladder voiding efficiency (BVE) that would predict surgical outcomes after GreenLight HPS<sup>TM</sup> laser photoselective vaporization of the prostate (HPS-PVP). Methods: A total of 193 patients underwent HPS-PVP were divided into two groups based on BVE: >75% (group-A) and ≤75% (group-B). BVE was calculated by dividing voided volume by voided volume plus PVR. Surgical outcomes were assessed from the ratio of the IPSS, the difference in Qmax and the difference in the quality of life IPSS subscore (QoL) before surgery and at 3, 12 and 36 months postoperatively. Results: There were significant improvements in all outcome measures after 3, 12, and 36 months; the improvement in Qmax was greater in group-A than group-B at each time point. The IPSS ratio was significantly greater in group-A than group-B at 3 months. There was no difference in QoL between the groups. The linear regression analysis showed that BVE correlated significantly with bladder outlet obstruction index, but not with prostate volume or age. In AUROC analysis, the BVE cut-off value of 75% showed highest sensitivity and specificity for predicting the success of surgical outcomes. Conclusions: Our results suggest that a large PVR may predict a relatively slight improvement in surgical outcomes after HPS-PVP. The cut-off value of PVR in predicting surgical success is 25% or more of residual fraction.
    Journal of endourology / Endourological Society 04/2014; DOI:10.1089/end.2014.0067 · 1.71 Impact Factor
  • Source
    Hyunsoo Ahn · Jae-Seung Paick · Soo Woong Kim ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose In the present study, we aimed to identify the incidence of fever in patients after subinguinal microsurgical varicocelectomy and to evaluate the clinical factors associated with the occurrence of the fever. Materials and Methods We retrospectively reviewed the cases of patients who underwent subinguinal microsurgical varicocelectomy (group A) under spinal anesthesia. In addition, we reviewed the cases of patients who underwent microsurgical vasovasostomy under spinal anesthesia as a control group (group B). The incidence of fever in each group was compared. We investigated the clinical factors influencing the occurrence of fever in the patients of group A. Results The incidence of fever in group A was significantly higher than that in group B (32.5% [53/163] vs. 0.4% [1/284]; p<0.001). Clinical factors such as age, varicocele grade, weight, height, operation time, number of ligated veins, usage of immediate postoperative analgesics, presence of postoperative hematoma, and duration of hospital stay were not significantly associated with the occurrence of fever. Conclusions We found that one-third of the patients developed transient fever after subinguinal microsurgical varicocelectomy, and therefore, this information should be provided during preoperative counseling.
    04/2014; 32(1):56-60. DOI:10.5534/wjmh.2014.32.1.56
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To show the noninferiority of silodosin 8-mg once-daily (QD) to 4-mg twice-daily (BID) in efficacy and safety in patients with lower urinary tract symptoms or benign prostatic hyperplasia in the Korean population. Methods A prospective, multicenter, double-blind, randomized, comparative study was conducted. A total of 532 male patients aged ≥50 years with lower urinary tract symptoms or benign prostatic hyperplasia were included. All patients received silodosin QD or BID for 12 weeks. The primary end point was the change from baseline in total International Prostate Symptom Score (IPSS) at 12 weeks. Adverse drug reactions, vital signs, and laboratory tests were recorded. Results A total of 424 patients were randomized to the silodosin QD or BID groups. These groups were not significantly different in baseline characteristics. The mean total IPSS change in QD group was not inferior to that in BID group (−6.70 and −6.94, respectively; 95% confidence interval, −0.88 to 1.36). The QD and BID groups did not significantly differ in the following: percentages of patients with ≥25% (63.41% and 67.82%, respectively; P = .349) or ≥4-point improvement in total IPSS (65.85% and 69.31%, respectively; P = .457), maximum urinary flow rate improvement ≥30% (47.32% and 40.59%, respectively; P = .172), changes in IPSS voiding subscore (−4.42 ± 4.93 and −4.65 ± 4.77; P = .641), IPSS storage subscore (−2.05 ± 3.07 and −2.52 ± 2.97; P = .117), quality of life (−1.19 ± 1.49 and −1.40 ± 1.42; P = .136), maximum urinary flow rate (3.55 ± 5.93 and 3.74 ± 6.79 mL/s; P = .768), International Continence Society male questionnaire score, Patient Goal Achievement Score, or Treatment Satisfaction Question. The 2 groups had similar frequencies of adverse drug reactions. Conclusion QD administration of silodosin was not inferior to BID in efficacy. The 2 groups had similar adverse drug reaction profiles.
    Urology 04/2014; 83(4). DOI:10.1016/j.urology.2013.11.013 · 2.19 Impact Factor

  • The Journal of Urology 04/2014; 191(4):e599-e600. DOI:10.1016/j.juro.2014.02.1663 · 4.47 Impact Factor
  • Sang Hoon Song · Woo Seok Choi · Hwancheol Son · Jae-Seung Paick ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Background The premature ejaculation diagnostic tool (PEDT) is a brief, multidimensional validated instrument devised for diagnosing premature ejaculation (PE). However, there is insufficient evidence regarding its ability to differentiate subgroups of PE. We assessed the ability of the PEDT to differentiate four subgroups of PE (lifelong, acquired, variable and subjective PE). Methods: An internet-based survey was conducted with a population-based sample of males aged 20-59 years. Participants were asked to complete a questionnaire requesting detailed medical and sexual histories. The questionnaire including questions from the PEDT and from the Medical Outcome Study Short-form 36-Item Health Survey (SF-36). Using the PEDT, PE was defined as a cutoff score of ≥11. Results: In this study, 443 subjects (mean age 39.3±10.1 years) were included. PEDT-PE prevalence was 14.6%. The proportions of PE subgroups and their mean PEDT scores were: lifelong PE, 2.9% and 15.5; acquired PE, 7.0% and 11.2; variable PE, 7.4% and 10.4; subjective PE, 3.2% and 9.0. PEDT scores were significantly higher in the lifelong PE group than in other the subgroups of PE (P<0.001). The subjective PE group had the lowest PEDT score, and their physical and mental component scores for the SF-36 were similar to those of non-PE subjects. Conclusions: This population-based cross-sectional survey has demonstrated that the PEDT is not appropriate for research into four subgroups of PE when used in an general male population study, unless the PEDT is combined with an additional questionnaire with specific questions on the four PE subgroups.
    Sexual Health 03/2014; 11(1):73-80. DOI:10.1071/SH13171 · 1.37 Impact Factor
  • Jin Kyu Oh · Jungbum Bae · Chang Wook Jeong · Jae-Seung Paick · Seung-June Oh ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The Holmium laser enucleation of the prostate (HoLEP) technique to remove residual adenoma has not been reported. Salvage HoLEP enables anatomical enucleation of residual adenoma in patients who have previously undergone surgical treatment. We describe not only anatomical insights into the frequent location of adenoma recurrence, but also the feasibility of the salvage HoLEP technique. Methods: We retrospectively reviewed a database containing HoLEP video records for 35 patients out of a total of 535 individuals on whom HoLEP was performed by 2 surgeons (SJO & JSP) between July 2008 and June 2011. Group 1 consisted of patients who underwent salvage HoLEP due to recurring adenoma and Group 2 of patients who underwent HoLEP as an initially surgical management to treat benign prostate hyperplasia (BPH). We compared the dataset of pre-, intra- and postoperative parameters between Groups 1 and 2. Results: In the analysis of the video records of Group 1 (n = 35), there was significant remnant tissue around the verumontanum and the lateral lobes were also incompletely removed by previous conventional procedures. When we compared pre-, intra- and postoperative parameters between the 2 groups, there were no significant differences, including operation time, duration of hospital stay. However, the duration of the catheterization of Group 1 was shorter than that of Group 2 (1.38 ± 0.55 vs. 1.90 ± 1.81 days, p < 0.001). Conclusions: Even for cases of residual BPH, salvage HoLEP is a feasible and effective procedure for treating residual adenoma along the anatomical plane.
    03/2014; 8(3-4):E235-40. DOI:10.5489/cuaj.1494

Publication Stats

2k Citations
376.11 Total Impact Points


  • 2003-2015
    • Seoul National University Hospital
      • Department of Urology
      Sŏul, Seoul, South Korea
  • 2014
    • University of Ulsan
      Urusan, Ulsan, South Korea
  • 1999-2014
    • Seoul National University
      • • Department of Urology
      • • College of Medicine
      • • Department of Medicine
      Sŏul, Seoul, South Korea
  • 2011
    • Muljibhai Patel Urological Hospital
      Aimand, Gujarat, India
  • 2006-2007
    • Seoul Veterans Hospital
      Sŏul, Seoul, South Korea
  • 2004
    • Yonsei University Hospital
      Sŏul, Seoul, South Korea